Information  X 
Enter a valid email address

Antisoma Research Limited (SRC)

  Print      Mail a friend       Annual reports

Tuesday 19 April, 2005

Antisoma Research Limited

IND granted for phase II study

AACR presentations on Antisoma's AS1404:
promising prostate and ovarian cancer data support trial plans

"US IND granted for phase II study in prostate cancer"


London, UK and American Association of Cancer Research Meeting,
Anaheim, CA, USA: 19 April 2005. Cancer drug developer Antisoma plc
(LSE:ASM) yesterday presented preclinical data showing that
combinations of its phase II drug AS1404 with the taxane drugs used
to treat prostate and ovarian cancers had significantly better
efficacy than the taxanes alone. The data support plans for
forthcoming clinical trials in these two cancers.

The US Food and Drug Administration has now approved an
'Investigational New Drug' (IND) application for a phase II study of
AS1404 in hormone-refractory prostate cancer. This study, in which
AS1404 will be combined with the taxane docetaxel, will start
shortly. A phase II study in recurrent ovarian cancer, where AS1404
will be combined with carboplatin and the taxane paclitaxel, is also
close to initiation in Europe, Australia and New Zealand. The phase
II programme began last year with a study of AS1404 with paclitaxel
in non-small cell lung cancer. Recruitment into this study is ongoing
in Australia and New Zealand, and the first efficacy findings are
expected this year.

In a further AACR presentation tomorrow, Dr Lesley McPhail of St
George's Hospital, London, UK, will show the correlation between
reduced tumour blood flow and necrosis (death) of tumours in rats
given doses of AS1404 equivalent to those currently being tested in
clinical trials.

Glyn Edwards, CEO of Antisoma, said: "The data presented at AACR show
the broad potential of AS1404 against different types of tumour and
support our plans to trial AS1404-taxane combinations in prostate and
ovarian cancers. We look forward to starting these studies and to the
first phase II results from our lung cancer trial, which we expect
during the second half of this year."

Note
The first presentation of Antisoma's phase I trial of AS1404 (DART)
will be made at the forthcoming ASCO meeting (May 13-17, Orlando,
Florida). Also to be presented at ASCO are results from the phase I
study of Antisoma's aptamer drug AS1411 (formerly AGRO100).

Enquiries:



Glyn Edwards, CEO, Antisoma plc +44 (0)20 8799 8200

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Buchanan Communications +44 (0)20 7466 5000

Richard Anderson

De Facto Communications +44(0)20 7940 1000 (ex-UK enquiries)





Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.


Background/Notes to Editors
AS1404 is a 'vascular disrupting agent' that attacks tumours by
targeting established tumour blood vessels that supply nutrients and
support further growth. Drugs in this class are distinct from
angiogenesis inhibitors, which block the growth of new tumour
vessels. AS1404 is amongst the leading small-molecule vascular
disrupting agents in clinical trials. The data presented at AACR are
consistent with many others in showing that the most effective use of
vascular disrupting agents is in combination approaches with other
cancer treatments.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. In 2002, Antisoma
formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. AS1404 is one of the
products included in this alliance. Please visit www.Antisoma.com for
further information about Antisoma.


---END OF MESSAGE---